November 1, 2008
By:Brittany Agro
Top Rx Club Award winners exhibit qualities that ironically juxtapose industry's paradigm (pdf)
 |
December 1, 2007
By:Joanna Breitstein
Science is the lifeblood of pharma, of course. But these days, science isn't just what you produce in your own labs. It's what you can license, buy, partner on, or gain through acquisition. Which means that, increasingly, deals are the lifeblood of pharma.
|
 | November 1, 2007
By:Joanna Breitstein
Photos from the awards ceremony of the first US Prix Galien, September 25, 2007 in New York City.
|
October 1, 2007
By:Albert I. Wertheimer, Ellen F. Loh, Lawrence G. Poli
Very few drugs live forever. Barring remarkable scientific advances and radical market dynamics, most drugs hit old age—and sharply declining sales—several years before their patent expires. But some drugs go out with a bang, not a whimper.
|
September 1, 2007
By:Bill Trombetta
For the sixth year in a row, Pharm Exec invites Professor Bill Trombetta of St. Joseph’s University to analyze the pharma industry's financial performance with a battery of business metrics, old and new. The highlights: Genentech pulls ahead of its longtime rival, Amgen. Forest delivers another strong performance, despite dropping revenue. Schering-Plough is building enterprise value. Biogen Idec racks up a stellar profit margin. And Merck? Well, Merck is back, baby. And the winner is…
|
 | December 1, 2005
By:Anthony Tao
Like the course of a pandemic itself, the great avian influenza scare came in waves. In 1997, the first case of the now infamous H5N1 strain of bird flu emerged in Hong Kong, infecting 18 people and killing six. In late 2003 it struck again—more than 120 people fell ill and at least 60 died over the next two years. Then this fall, David Nabarro, MD, the UN coordinator for avian and human influenza, shocked everyone when he said a bird flu pandemic could claim up to 150 million lives—a figure the World Health Organization (WHO) quickly retracted.
|
 | December 1, 2005
By:Grant Winter
Despite heightened scrutiny from industry advocates and the beginnings of self-imposed regulation, pharma companies' violations of DTC regulations have been getting worse, says Tom Abrams, director of FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC). Abrams has been on all sides of drug marketing, from receiving promotions as a pharmacist to creating promotions as a member of industry to regulating promotions as the head of DDMAC. As such, he's in good position to see the big picture.
|
 | December 1, 2005
By:Ron Feemster
Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and—at last—innovative mechanisms for troublesome targets.
|
 | December 1, 2005
By:Patrick Clinton
Medicare Part D launches. $23 billion worth of patents expire. FDA wrestles with safety issues. Pharma prepares for unprecedented cost cutting and restructuring. 2006 promises to be banner year—if you like roller coasters.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?
Super Reps book trilogy by Dr. Lou Sawaya MD, MBA
Don't miss this Podcast series commemorating the 20th anniversary of HBA's Woman of the Year Award with interviews spanning two decades of change makers.
Conducting clinical trials in emerging regions can give you the edge. Five Quintiles experts share their insights into navigating the global regulatory landscape.